Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

ss applicable to common stock of $2.7 million, or ($0.17) per share, basic and diluted, compared with a net loss of $3.7 million or ($0.29) per share for the same period in 2011. For the full year 2012, the Company reported a net loss applicable to common stock of $10.9 million, or ($0.72) per share, basic and diluted, compared with a net loss of $12.7 million, or $(1.06) per share in 2011. The full year 2012 results include $0.2 million of other income as well as $1.2 million of non-cash expense related to dividends and accretion on the preferred stock compared with $1.8 million in 2011. The weighted average number of shares used to calculate loss per share increased for the 2012 periods compared to the 2011 periods due primarily to the March 2012 offering of 2.7 million common shares as well as the payment of dividends in common stock.

Research and development expense for the fourth quarter of 2012 was $1.0 million, compared with $0.9 million for the same period in 2011. Research and development expense for the full year 2012, was $4.5 million, compared with $3.6 million in 2011. The increase for the fourth quarter and the year-over-year expenses is due primarily to increased pre-clinical activity in our fibrosis program as we prepared to file an IND in January 2013 and begin a Phase I clinical trial, offset by decreased expenses related to stock-based compensation.General and administrative expense for the fourth quarter of 2012 was $1.4 million, compared with $2.5 million for the same period in 2011. General and administrative expense for the full year 2012 was $5.4 million as compared to $6.9 million for 2011. The decrease for the fourth quarter and full year 2012 is due primarily to the recognition of a $1.0 million payment related to a separation agreement during the fourth quarter of 2011. Additionally, the decrease in expense for the fourth quarter and full year 2012 is due primarily to overall decreased business development costs as we decreased wor
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 2015 Pharmaco-Kinesis Corporation (PKC) announced today that ... Shutters on the Beach in Santa Monica, ... the Company,s innovative Metronomic Biofeedback Pump (MBP), a fully ... over time to a target site of the human ... system in real-time.  ...
(Date:5/26/2015)... -- Mr. Kevin Xu , President of MEBO International, ... and President Bill Clinton for their sympathy ... Rongxiang Xu , Kevin,s father. As ... time, Dr. Xu,s commitment to the advancement of science and ... not be forgotten. As a renowned life scientist, Dr. Xu ...
(Date:5/26/2015)... TORONTO , May 26, 2015 /PRNewswire/ - Fluorinov ... appointment of Luke M. Beshar to its ... adding financial and pharmaceutical industry expertise as Fluorinov accelerates ... of the Fluorinov team, it is a pleasure to ... had a significant impact on the strategy, financial strength ...
(Date:5/26/2015)... CA (PRWEB) May 26, 2015 ... officially joining the Alliance for Regenerative Medicine (ARM). ... fostering research, development, investment, and commercialization of transformational ... PRC Clinical, the California-based CRO focused in ... in stem cell and regenerative research working with ...
Breaking Biology Technology:Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Dr. Rongxiang Xu, Beyond A Legend 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3PRC Clinical Joins 200+ Member Organizations in The Alliance for Regenerative Medicine (ARM) 2PRC Clinical Joins 200+ Member Organizations in The Alliance for Regenerative Medicine (ARM) 3
... The National Eye ... grant to Aciont Inc. to help fund its development of a non-invasive, passive diffusion-based treatment ... ... (NEI), a division of the National Institutes of Health (NIH), awarded a $2.18 million grant ...
... ... a world-leading provider of advanced flow measurement, control, and level solutions, ... Product Manager effective November 30, 2009. He will lead Brooks Instrument’s ... the world. He is joining Brooks Instrument from Lafarge Corp, a ...
... , SAN DIEGO, Dec. 10 ... announces the release of SampleWare 3.1 software system for laboratory ... now includes an audit trail functionality that tracks user and ... stored sample. , The addition of the audit trail ...
Cached Biology Technology:NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 3Biomatrica Launches SampleWare 3.1 2Biomatrica Launches SampleWare 3.1 3
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... and flu expert is calling for mandatory vaccination of ... protecting patients and hospital staff from widespread outbreaks of ... researchers show that voluntary vaccination programs don't do the ... from influenza, many of them elderly or ill, with ...
... this week in Nature shows for the first time ... cells that regulate daily activity of Drosophila melanogaster (fruit ... and evening activity and are maintained in synch even ... periods of time. , This daily resetting signal ...
... a whiff of food that has made them sick in ... ?and to prevent them from eating that food again. It's ... biology that it occurs in a broad range of species. ... smells associated with foods that have made them ill. ...
Cached Biology News:Johns Hopkins flu expert calls for mandatory vaccination of health care workers 2Johns Hopkins flu expert calls for mandatory vaccination of health care workers 3A resetting signal keeps circadian rhythm on track in Drosophila fruit flies 2Worms know bad food when they smell it 2Worms know bad food when they smell it 3Worms know bad food when they smell it 4
Blasticidin resistance gene (bsr), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... flasks have triple baffles located at the ... maximal oxygen transfer to culture medium. These ... wide range of optional caps are available ... caps for ease of sorting and identification ...
...
... These 2800mL wide mouth PYREX Fernbach-style culture ... center of the flask bottom to achieve ... triple baffled flasks have a Delong-style 38mm ... steel closures. For plastic closures see Nos. ...
Biology Products: